AVX 13616 |
| Catalog No.GC35439 |
AVX 13616은 Avexa의 주요 항균 후보물질의 강력한 생체 내 항균 활성을 보여줍니다. 특히 약물 내성 포도상 구균 병원체에 대해.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 900814-48-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
AVX 13616 shows the potent in vivo antibacterial activity of Avexa's lead antibacterial candidate; particularly against drug-resistant Staphylococcus pathogens.IC50 value: 2-4 ug/ml (MICs)Target: antibacterial agent AVX13616 was as active as mupirocin in a nasal decolonization model but required only a single application. The compounds are being developed for topical indications and/or wound infection/catheter-related infections. AVX13616 and other compounds showed broad spectrum antibacterial activity against a range of isolates with MICs of 2-4 micrograms per millilitre against S. aureus, coagulase negative staphylococci, enterococci, MRSA, VISA and VRSA. A single application of 5% (w/w) AVX13616 (approximately equimolar to 2% mupirocin) was as effective as 2% mupirocin administered twice a day for five days in nasal decolonisation of MRSA in mice.
[1]. Avexa Presents Data from Apricitabine and Antibacterial Programs at two International Conferences
Average Rating: 5 (Based on Reviews and 3 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *